Noradrenaline Kabi (Noradrenaline Tartrate)

Norepinephrine (noradrenaline) binds directly to alpha‑1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction and raising systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, which enhances myocardial contractility and cardiac output. The combined effect elevates arterial pressure and improves tissue perfusion.

The dose of Noradrenaline Kabi is individualized. A qualified prescriber determines the initial infusion rate and subsequent titration based on the patient’s blood pressure, cardiac output, and overall clinical response. Continuous hemodynamic monitoring is essential to adjust the dose safely.

Safety data for Noradrenaline Kabi in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. The decision must be made by the treating physician in consultation with obstetric specialists.

To order Noradrenaline Kabi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Noradrenaline is often preferred over dopamine because it provides potent alpha‑mediated vasoconstriction with less tachyarrhythmia risk. Compared with phenylephrine, it also offers beta‑1 stimulation, which can improve cardiac output. Choice of vasopressor depends on the clinical scenario, patient comorbidities, and physician preference.

Noradrenaline Kabi must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing. Do not shake the solution; gently invert if mixing is required. Inspect the product before use for any particulate matter or discoloration.

The product is supplied as a sterile solution for injection and is administered intravenously, usually via a dedicated infusion line. It is given as a continuous infusion that is titrated to the desired blood pressure response. Compatibility with other IV drugs should be checked before co‑administration.

The most serious adverse events include severe hypertension, myocardial ischemia or infarction, and extravasation injury leading to tissue necrosis. Prompt recognition and management of these complications are essential, and infusion rates should be adjusted or stopped if they occur.

Noradrenaline Kabi is contraindicated in patients with uncorrected pheochromocytoma, severe peripheral vascular disease, or known hypersensitivity to the product. Caution is also advised in patients with acute myocardial infarction, severe arrhythmias, or uncontrolled hypertension.